Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Ann Oncol. 2023 Jan 25;34(4):397–409. doi: 10.1016/j.annonc.2023.01.009

Figure 5. Framework for genomic subgrouping of premenopausal HRDHER2− breast cancer.

Figure 5.

(A) Proposed framework for genomic subgrouping for premenopausal patients with HR+HER2− early breast cancers, and number of patients with each feature in the SOFT combined sequencing cohort (n = 1276). (B) Venn diagram demonstrating the number and proportion of tumours assigned to each poor prognosis genomic subgroup in the SOFT combined sequencing cohort (n = 1276) using the proposed framework. (C) Pie charts demonstrating the frequencies of the proposed genomic subgroups according to age at randomisation in the SOFT combined sequencing cohort (n = 1276). (D) Kaplan–Meier plot estimating the rate of freedom from distant recurrence according to the proposed genomic subgroups in the SOFT combined sequencing cohort (n = 1276). (E) Kaplan–Meier plot estimating the overall survival according to the proposed genomic subgroups in the SOFT combined sequencing cohort (n = 1276).

CI, confidence interval; CNA, copy number amplification; ER, estrogen receptor; HER2−, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; HRD, homologous recombination deficiency; SOFT, Suppression of Ovarian Function Trial.